• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿路上皮膀胱癌不同阶段的比较蛋白质组学分析以鉴定潜在生物标志物:抗氧化活性的突出作用

Comparative proteomics analysis in different stages of urothelial bladder cancer for identification of potential biomarkers: highlighted role for antioxidant activity.

作者信息

Tabaei Samira, Haghshenas Mohammad Reza, Ariafar Ali, Gilany Kambiz, Stensballe Allan, Farjadian Shirin, Ghaderi Abbas

机构信息

Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

出版信息

Clin Proteomics. 2023 Jul 27;20(1):28. doi: 10.1186/s12014-023-09419-8.

DOI:10.1186/s12014-023-09419-8
PMID:37501157
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10373361/
Abstract

BACKGROUND

Non-muscle-invasive bladder cancer (NMIBC) has a high recurrence rate and muscle-invasive bladder cancer (MIBC) has unfavorable outcomes in urothelial bladder cancer (UBC) patients. Complex UBC-related protein biomarkers for outcome prediction may provide a more efficient management approach with an improved clinical outcome. The aim of this study is to recognize tumor-associated proteins, which are differentially expressed in different stages of UBC patients compared non-cancerous tissues.

METHODS

The proteome of tissue samples of 42 UBC patients (NMIBC n = 25 and MIBC n = 17) was subjected to two-dimensional electrophoresis (2-DE) combined with Liquid chromatography-mass spectrometry (LC-MS) system to identify differentially expressed proteins. The intensity of protein spots was quantified and compared with Prodigy SameSpots software. Functional, pathway, and interaction analyses of identified proteins were performed using geneontology (GO), PANTHER, Reactome, Gene MANIA, and STRING databases.

RESULTS

Twelve proteins identified by LC-MS showed differential expression (over 1.5-fold, p < 0.05) by LC-MS, including 9 up-regulated in NMIBC and 3 up-regulated in MIBC patients. Proteins involved in the detoxification of reactive oxygen species and cellular responses to oxidative stress showed the most significant changes in UBC patients. Additionally, the most potential functions related to these detected proteins were associated with peroxidase, oxidoreductase, and antioxidant activity.

CONCLUSION

We identified several alterations in protein expression involved in canonical pathways which were correlated with the clinical outcomes suggested might be useful as promising biomarkers for early detection, monitoring, and prognosis of UBC.

摘要

背景

在尿路上皮膀胱癌(UBC)患者中,非肌层浸润性膀胱癌(NMIBC)复发率高,而肌层浸润性膀胱癌(MIBC)预后不佳。用于预后预测的复杂UBC相关蛋白质生物标志物可能提供一种更有效的管理方法,改善临床结果。本研究的目的是识别与肿瘤相关的蛋白质,这些蛋白质在UBC患者的不同阶段与非癌组织相比存在差异表达。

方法

对42例UBC患者(NMIBC患者25例,MIBC患者17例)的组织样本蛋白质组进行二维电泳(2-DE)结合液相色谱-质谱(LC-MS)系统分析,以鉴定差异表达的蛋白质。使用Prodigy SameSpots软件对蛋白质斑点的强度进行定量和比较。利用基因本体论(GO)、PANTHER、Reactome、Gene MANIA和STRING数据库对鉴定出的蛋白质进行功能、通路和相互作用分析。

结果

LC-MS鉴定出的12种蛋白质显示出差异表达(超过1.5倍,p<0.05),其中9种在NMIBC患者中上调,3种在MIBC患者中上调。参与活性氧解毒和细胞对氧化应激反应的蛋白质在UBC患者中变化最为显著。此外,与这些检测到的蛋白质最相关的潜在功能与过氧化物酶、氧化还原酶和抗氧化活性有关。

结论

我们确定了几种参与经典通路的蛋白质表达改变,这些改变与临床结果相关,可能有望作为UBC早期检测、监测和预后的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2194/10373361/62a4b35e6500/12014_2023_9419_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2194/10373361/76c7ab97cfc4/12014_2023_9419_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2194/10373361/e7b77726d339/12014_2023_9419_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2194/10373361/b8168dc6a11f/12014_2023_9419_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2194/10373361/28fd23d54b1c/12014_2023_9419_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2194/10373361/62a4b35e6500/12014_2023_9419_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2194/10373361/76c7ab97cfc4/12014_2023_9419_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2194/10373361/e7b77726d339/12014_2023_9419_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2194/10373361/b8168dc6a11f/12014_2023_9419_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2194/10373361/28fd23d54b1c/12014_2023_9419_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2194/10373361/62a4b35e6500/12014_2023_9419_Fig5_HTML.jpg

相似文献

1
Comparative proteomics analysis in different stages of urothelial bladder cancer for identification of potential biomarkers: highlighted role for antioxidant activity.尿路上皮膀胱癌不同阶段的比较蛋白质组学分析以鉴定潜在生物标志物:抗氧化活性的突出作用
Clin Proteomics. 2023 Jul 27;20(1):28. doi: 10.1186/s12014-023-09419-8.
2
Dynamic expression changes between non-muscle-invasive bladder cancer and muscle-invasive bladder cancer.非肌层浸润性膀胱癌与肌层浸润性膀胱癌之间的动态表达变化。
Tumori. 2014 Nov-Dec;100(6):e273-81. doi: 10.1700/1778.19294.
3
Comparative bioinformatics analysis of prognostic and differentially expressed genes in non-muscle and muscle invasive bladder cancer.非肌肉浸润性膀胱癌和肌肉浸润性膀胱癌预后和差异表达基因的比较生物信息学分析。
J Proteomics. 2020 Oct 30;229:103951. doi: 10.1016/j.jprot.2020.103951. Epub 2020 Aug 27.
4
The prognostic value of family history among patients with urinary bladder cancer.膀胱癌患者家族史的预后价值。
Int J Cancer. 2015 Mar 1;136(5):1117-24. doi: 10.1002/ijc.29062. Epub 2014 Jul 9.
5
Heterogeneity research in muscle-invasive bladder cancer based on differential protein expression analysis.基于差异蛋白表达分析的肌层浸润性膀胱癌异质性研究
Med Oncol. 2014 Sep;31(9):21. doi: 10.1007/s12032-014-0021-9. Epub 2014 Aug 2.
6
Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer.蛋白质组学鉴定PGAM1作为膀胱尿路上皮癌的潜在治疗靶点。
J Proteomics. 2016 Jan 30;132:85-92. doi: 10.1016/j.jprot.2015.11.027. Epub 2015 Dec 3.
7
Proteomics strategies for urothelial bladder cancer diagnosis, prognosis and treatment: Trends for tumor biomarker sources.尿路上皮膀胱癌诊断、预后和治疗的蛋白质组学策略:肿瘤生物标志物来源的趋势
Anal Biochem. 2023 Apr 1;666:115074. doi: 10.1016/j.ab.2023.115074. Epub 2023 Feb 2.
8
Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.根治性膀胱切除术后原发性与复发性高危非肌层浸润性膀胱癌以及原发性与继发性肌层浸润性膀胱癌的比较结果:一项回顾性多中心研究的结果
Eur Urol Open Sci. 2022 Apr 1;39:14-21. doi: 10.1016/j.euros.2022.02.011. eCollection 2022 May.
9
Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing.通过全外显子测序对中国人群非肌层浸润性和肌层浸润性膀胱癌中差异突变基因的比较分析
Front Genet. 2022 Mar 25;13:831146. doi: 10.3389/fgene.2022.831146. eCollection 2022.
10
The Association Between Gelsolin-like Actin-capping Protein (CapG) Overexpression and Bladder Cancer Prognosis.肌动蛋白封端蛋白(CapG)过表达与膀胱癌预后的关系。
Urol J. 2020 Aug 31;18(2):186-193. doi: 10.22037/uj.v0i0.5664.

引用本文的文献

1
Investigation of new autoantibodies in urothelial bladder cancer for biomarker discovery using immunoproteomics.利用免疫蛋白质组学研究尿路上皮膀胱癌中的新型自身抗体以发现生物标志物。
Discov Oncol. 2025 Mar 31;16(1):436. doi: 10.1007/s12672-025-02167-1.
2
Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non-muscle-invasive bladder cancer using multi-layered studies.运用多层次研究解析中高危和(极)高危非肌层浸润性膀胱癌的分子异质性
Front Oncol. 2024 Oct 21;14:1424293. doi: 10.3389/fonc.2024.1424293. eCollection 2024.
3
Inferring Bladder Cancer Evolution from Mucosal field Effects by Whole-Organ Spatial Mutational, Proteomic, and Metabolomic Mapping.

本文引用的文献

1
Proteomics strategies for urothelial bladder cancer diagnosis, prognosis and treatment: Trends for tumor biomarker sources.尿路上皮膀胱癌诊断、预后和治疗的蛋白质组学策略:肿瘤生物标志物来源的趋势
Anal Biochem. 2023 Apr 1;666:115074. doi: 10.1016/j.ab.2023.115074. Epub 2023 Feb 2.
2
Potential Role of Seven Proteomics Tissue Biomarkers for Diagnosis and Prognosis of Prostate Cancer in Urine.七种蛋白质组学组织生物标志物在前列腺癌尿液诊断和预后中的潜在作用
Diagnostics (Basel). 2022 Dec 16;12(12):3184. doi: 10.3390/diagnostics12123184.
3
Epidemiology, Screening, and Prevention of Bladder Cancer.
通过全器官空间突变、蛋白质组学和代谢组学图谱从黏膜场效应推断膀胱癌的演变
Res Sq. 2024 Apr 10:rs.3.rs-3994376. doi: 10.21203/rs.3.rs-3994376/v1.
4
Exploration of potential biomarkers for early bladder cancer based on urine proteomics.基于尿液蛋白质组学探索早期膀胱癌的潜在生物标志物
Front Oncol. 2024 Feb 12;14:1309842. doi: 10.3389/fonc.2024.1309842. eCollection 2024.
膀胱癌的流行病学、筛查与预防
Eur Urol Oncol. 2022 Dec;5(6):628-639. doi: 10.1016/j.euo.2022.10.003. Epub 2022 Nov 1.
4
Targeting PGAM1 in cancer: An emerging therapeutic opportunity.靶向 PGAM1 治疗癌症:一种新兴的治疗机会。
Eur J Med Chem. 2022 Dec 15;244:114798. doi: 10.1016/j.ejmech.2022.114798. Epub 2022 Oct 3.
5
A Liquid Biopsy in Bladder Cancer-The Current Landscape in Urinary Biomarkers.膀胱癌的液体活检——尿液生物标志物的现状。
Int J Mol Sci. 2022 Aug 2;23(15):8597. doi: 10.3390/ijms23158597.
6
Peroxiredoxins - Urinary Surveillance Biomarkers in Urothelial Cancer.过氧化物还原酶——尿路上皮癌的尿液监测生物标志物
J Cancer. 2022 Jun 13;13(9):2751-2756. doi: 10.7150/jca.69811. eCollection 2022.
7
Advances in Diagnosis and Therapy for Bladder Cancer.膀胱癌诊断与治疗的进展
Cancers (Basel). 2022 Jun 29;14(13):3181. doi: 10.3390/cancers14133181.
8
Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor.经尿道膀胱肿瘤切除术治疗后 pTa 膀胱癌复发的临床决定因素。
BMC Cancer. 2022 Jun 8;22(1):631. doi: 10.1186/s12885-022-09733-8.
9
Biliverdin reductase bridges focal adhesion kinase to Src to modulate synaptic signaling.胆红素还原酶将黏着斑激酶连接到Src,从而调节突触信号转导。
Sci Signal. 2022 May 10;15(733):eabh3066. doi: 10.1126/scisignal.abh3066.
10
Proteomics for Early Detection of Non-Muscle-Invasive Bladder Cancer: Clinically Useful Urine Protein Biomarkers.蛋白质组学用于非肌层浸润性膀胱癌的早期检测:具有临床应用价值的尿液蛋白质生物标志物
Life (Basel). 2022 Mar 9;12(3):395. doi: 10.3390/life12030395.